clinical trial · NCT05529901
Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder
W.L.Gore & Associates·—·active not recruiting·n = 300
StrokePFO - Patent Foramen OvaleCryptogenic StrokeTIAGORE® CARDIOFORM Septal Occluder
brief summary
The purpose of this post-marketing surveillance is to evaluate the effectiveness and safety of GORE® CARDIOFORM Septal Occluder under the post-marketing setting in Japan.
started
Oct 3, 2022
primary completion
Aug 1, 2029
completion
Aug 1, 2029
last updated
Nov 20, 2025
official title
Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol